

## MESOBLAST CORPORATE UPDATE AND FINANCIAL RESULTS WEBCAST

**Melbourne, Australia, November 20, and New York, USA, November 19, 2020:** Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to provide a corporate update, and report financial and operational highlights for the first quarter ended September 30, 2020 (FY2021).

### Conference Call Details

The webcast will begin at 9.00am AEDT, Friday, November 20; 5.00pm EST, Thursday, November 19, 2020. It can be accessed via <https://webcast.boardroom.media/mesoblast-limited/20201119/NaN5fb59c68f297810019932232>

The archived webcast will be available on the Investor page of the Company's website:

[www.mesoblast.com](http://www.mesoblast.com)

### About Mesoblast

Mesoblast Limited (ASX:MSB; Nasdaq:MESO) is a world leader in developing allogeneic (off-the-shelf) cellular medicines. The Company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of commercial products and late-stage product candidates. Mesoblast has a strong and extensive global intellectual property (IP) portfolio with protection extending through to at least 2040 in all major markets. The Company's proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.

Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid-refractory acute graft versus host disease and moderate to severe acute respiratory distress syndrome. Mesoblast is completing Phase 3 trials for its product candidates for advanced heart failure and chronic low back pain. Two products have been commercialized in Japan and Europe by Mesoblast's licensees, and the Company has established commercial partnerships in Europe and China for certain Phase 3 assets.

Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see [www.mesoblast.com](http://www.mesoblast.com), LinkedIn: Mesoblast Limited and Twitter: @Mesoblast

Release authorized by the Chief Executive.

*For further information, please contact:*

### Media

Julie Meldrum  
T: +61 3 9639 6036  
E: [julie.meldrum@mesoblast.com](mailto:julie.meldrum@mesoblast.com)

Kristen Bothwell  
T: +1 917 613 5434  
E: [kbothwell@rubenstein.com](mailto:kbothwell@rubenstein.com)

### Investors

Schond Greenway  
T: +212 880 2060  
E: [schond.greenway@mesoblast.com](mailto:schond.greenway@mesoblast.com)

Paul Hughes  
T: +61 3 9639 6036  
E: [paul.hughes@mesoblast.com](mailto:paul.hughes@mesoblast.com)